Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
EMERYVILLE, Calif., May 04, 2018 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2018, after the market close, and will host a corporate update conference call and webcast on Wednesday, May 9, 2018, at 4:30 PM Eastern Time.
Conference Call Details
Wednesday, May 9th @ 4:30pm Eastern Time/1:30pm Pacific Time
| Toll Free: | 866-548-4713 |
| International: | 323-794-2093 |
| Conference ID: | 7186111 |
| Webcast: | http://public.viavid.com/index.php?id=129538 |
| Replays, available through May 23rd | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Replay PIN: | 7186111 |
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors:
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987
[email protected]
